Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420651 · ClinicalTrials.gov registry record · NA
Peak Expiratory Flow Rate for Emergency Department Management of Acute Asthma Exacerbation
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 188
- Enrollment target
NCT03420651: Completed NA study, sponsored by Hennepin Healthcare Research Institute.
NCT03420651 is a NA study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 188 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03420651, a NA study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
Study Summary
Patients presenting to the emergency department with acute asthma exacerbation will be assigned to peak-expiratory flow rate (PEFR) guided management and non-PEFR guided management.
Primary Outcome
Proportion of patients reporting no or mild asthma symptoms at 150 minutes after enrollment
Interventions
- OTHER Peak Expiratory Flow Rate (PEFR)
- OTHER Standard Clinical Judgement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2022-11-30 |
| Phase | NA |
What the finished NCT03420651 record still lists
NCT03420651 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Peak Expiratory Flow Rate (PEFR) is the first listed.
NCT03420651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03420651 about?
NCT03420651 is a clinical study titled "Peak Expiratory Flow Rate for Emergency Department Management of Acute Asthma Exacerbation". Patients presenting to the emergency department with acute asthma exacerbation will be assigned to peak-expiratory flow rate (PEFR) guided management and non-PEFR guided management.
What is the current status of trial NCT03420651?
This trial is currently completed. It is a NA study. The enrollment target is 188 participants. The study started on 2018-01-19. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT03420651?
The interventions under investigation include: Peak Expiratory Flow Rate (PEFR) (OTHER), Standard Clinical Judgement (OTHER).
Who is sponsoring clinical trial NCT03420651?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03420651's enrollment target sits among peer trials
188 576th of 2000 higher than 1,422 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI